Craig M Brackett
Overview
Explore the profile of Craig M Brackett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lieberman M, Tong J, Odukwe N, Chavel C, Purdon T, Burchett R, et al.
bioRxiv
. 2024 Apr;
PMID: 38562904
Recent FDA approvals of chimeric antigen receptor (CAR) T cell therapy for multiple myeloma (MM) have reshaped the therapeutic landscape for this incurable cancer. In pivotal clinical trials B cell...
2.
Tzetzo S, Kramer E, Mohammadpour H, Kim M, Rosario S, Yu H, et al.
iScience
. 2024 Feb;
27(3):109187.
PMID: 38420590
Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic sites, yet their functional contributions to metastasis remain incompletely understood. Here, we show that alveolar macrophages (AMs), the main TRMs of...
3.
Kramer E, Tzetzo S, Colligan S, Hensen M, Brackett C, Clausen B, et al.
JCI Insight
. 2023 Apr;
8(8).
PMID: 37092550
The main cause of malignancy-related mortality is metastasis. Although metastatic progression is driven by diverse tumor-intrinsic mechanisms, there is a growing appreciation for the contribution of tumor-extrinsic elements of the...
4.
Shah S, Gillard B, Wrobel M, Karasik E, Moser M, Mastri M, et al.
Front Oncol
. 2023 Feb;
13:1120329.
PMID: 36816919
Introduction: Bladder cancer is a heterogenous disease and the emerging knowledge on molecular classification of bladder tumors may impact treatment decisions based on molecular subtype. Pre-clinical models representing each subtype...
5.
Brackett C, Greene K, Aldrich A, Trageser N, Pal S, Molodtsov I, et al.
Cell Death Discov
. 2021 Sep;
7(1):266.
PMID: 34584068
Acute radiation syndrome (ARS) is a major cause of lethality following radiation disasters. A TLR5 agonist, entolimod, is among the most powerful experimental radiation countermeasures and shows efficacy in rodents...
6.
Fedtsova N, Komarova E, Greene K, Novototskaya L, Molodtsov I, Brackett C, et al.
Cell Death Dis
. 2021 May;
12(6):545.
PMID: 34039962
Transplantation of bone marrow (BM) is made possible by the differential sensitivity of its stromal and hematopoietic components to preconditioning by radiation and/or chemotherapeutic drugs. These genotoxic treatments eliminate host...
7.
Mett V, Kurnasov O, Bespalov I, Molodtsov I, Brackett C, Burdelya L, et al.
Commun Biol
. 2021 Apr;
4(1):466.
PMID: 33846531
The Toll-like receptor 5 (TLR5) agonist entolimod, a derivative of Salmonella flagellin, has therapeutic potential for several indications including radioprotection and cancer immunotherapy. However, in Phase 1 human studies, entolimod...
8.
Chen M, Brackett C, Burdelya L, Punnanitinont A, Patnaik S, Matsuzaki J, et al.
Cancer Immunol Immunother
. 2021 Jan;
70(7):2073-2086.
PMID: 33439292
Curaxins are small molecules that bind genomic DNA and interfere with DNA-histone interactions leading to the loss of histones and decondensation of chromatin. We named this phenomenon 'chromatin damage'. Curaxins...
9.
Haderski G, Kandar B, Brackett C, Toshkov I, Johnson C, Paszkiewicz G, et al.
PLoS One
. 2020 Feb;
15(2):e0227940.
PMID: 32027657
Tumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the...
10.
Brackett C, Kojouharov B, Veith J, Greene K, Burdelya L, Gollnick S, et al.
Proc Natl Acad Sci U S A
. 2016 Feb;
113(7):E874-83.
PMID: 26831100
Activation of an anticancer innate immune response is highly desirable because of its inherent ability to generate an adaptive antitumor T-cell response. However, insufficient safety of innate immune modulators limits...